Literature DB >> 14767510

Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis.

Tetsuya Saito1, Norihiro Masuda, Tatsuya Miyazaki, Kenichi Kanoh, Hideki Suzuki, Tatsuo Shimura, Takayuki Asao, Hiroyuki Kuwano.   

Abstract

Recently, overexpression of EphA2, a member of the Eph family of receptor tyrosine kinases, has been reported in several cancers. Reduced expression of E-cadherin, an intercellular adhesion molecule of epithelial cells, has been reported to be associated with aggressive clinicopathological phenotypes in various cancers. In epithelial cells, EphA2 and E-cadherin co-localize to sites of cell-cell contact, and it has been shown that E-cadherin regulates EphA2. This study aimed to clarify the relationship between the expression of the EphA2 and E-cadherin proteins and clinicopathological characteristics, with reference to the expression levels of both EphA2 and E-cadherin, in patients with colorectal cancer. We performed immunohistochemical staining of EphA2 and E-cadherin with EphA2 and E-cadherin monoclonal antibodies in samples from 194 primary lesions of colorectal cancer. The expression level of EphA2 had a statistically significant relationship with liver metastasis, lymphatic vessel invasion and clinical stage (p=0.0477, 0.0316 and 0.0467, respectively). In addition, the positivity rate of EphA2 was significantly higher in primary lesions with lymph node metastasis than in those without metastasis (p=0.0014). However, the expression level of E-cadherin had an inverse relationship with both differentiation level of the tumor and lymphatic vessel invasion (p=0.0430 and 0.0320, respectively). Furthermore, a significant relationship between the expression of EphA2 and E-cadherin was observed. In conclusion, our study revealed that the overexpression of EphA2 protein in colorectal carcinoma tissue correlates closely with cancer progression and hematogenous and lymphogenous metastasis, suggesting that both EphA2 and E-cadherin may play an important role in tumor metastasis in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767510

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  45 in total

Review 1.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

2.  Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Authors:  Stamatios Theocharis; Jerzy Klijanienko; Constantinos Giaginis; Paraskevi Alexandrou; Efstratios Patsouris; Xavier Sastre-Garau
Journal:  Pathol Oncol Res       Date:  2013-09-11       Impact factor: 3.201

3.  Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.

Authors:  Weibo Cai; Alireza Ebrahimnejad; Kai Chen; Qizhen Cao; Zi-Bo Li; David A Tice; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-03       Impact factor: 9.236

Review 4.  A review of spatial computational models for multi-cellular systems, with regard to intestinal crypts and colorectal cancer development.

Authors:  Giovanni De Matteis; Alex Graudenzi; Marco Antoniotti
Journal:  J Math Biol       Date:  2012-05-08       Impact factor: 2.259

5.  Receptor Tyrosine Kinase EphB3: a Prognostic Indicator in Colorectal Carcinoma.

Authors:  Zhuoqi Xuan; Jianming Huang; Lin Gao; Yong Wang; Jiandong Wang; Yueming Sun
Journal:  Pathol Oncol Res       Date:  2018-12-07       Impact factor: 3.201

6.  Computational model of cell positioning: directed and collective migration in the intestinal crypt epithelium.

Authors:  Shek Yoon Wong; K-H Chiam; Chwee Teck Lim; Paul Matsudaira
Journal:  J R Soc Interface       Date:  2010-03-31       Impact factor: 4.118

Review 7.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

8.  Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth.

Authors:  David Kiewlich; Jianhuan Zhang; Cynthia Gross; Wei Xia; Brent Larsen; Ronald R Cobb; Sandra Biroc; Jian-Ming Gu; Takashi Sato; David R Light; Tara Heitner; Joerg Willuda; David Vogel; Felipe Monteclaro; Andrzej Citkowicz; Steve R Roffler; Deborah A Zajchowski
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

9.  Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival.

Authors:  N I Herath; J Doecke; M D Spanevello; B A Leggett; A W Boyd
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

10.  Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.

Authors:  Erin B Dickerson; William H Blackburn; Michael H Smith; Laura B Kapa; L Andrew Lyon; John F McDonald
Journal:  BMC Cancer       Date:  2010-01-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.